Illumina Inc. | Key People and Executives
Jay T. Flatley
Executive Chairman
Francis A. deSouza
President, Chief Executive Officer & Director
Frances Hamilton Arnold
Director
Karin Eastham
Independent Director
Arthur Blaine Bowman
Lead Independent Director
John Wendell Thompson
Independent Director
Philip W. Schiller
Independent Director
Caroline D. Dorsa
Independent Director
Robert S. Epstein
Independent Director
Jay T. Flatley
Executive Chairman
Francis A. deSouza
President, Chief Executive Officer & Director
Ostadan Omead
Executive Vice President-Products & Operations
Sam A. Samad
Chief Financial Officer & Senior Vice President
Phillip G. Febbo
Chief Medical Officer
Mostafa Ronaghi
Chief Technology Officer & Senior Vice President
Mark Van Oene
Chief Commercial Officer & Senior Vice President
Marc A. Stapley
EVP-Strategy & Corporate Development
Garret Hampton
Executive Vice President-Clinical Genomics
Paula Dowdy
Senior Vice President
Sanjay Chikarmane
Senior VP & General Manager-Enterprise Informatics
Frances Hamilton Arnold
Director
Rebecca Chambers
Treasury
Karen K. McGinnis
Chief Accounting Officer & Vice President
Jacquie Ross
Vice President-Investor Relations
Eric Endicott
Senior Director-Corporate Communications
Aimee Hoyt
Chief People Officer & Senior Vice President
Charles E. Dadswell
Secretary, Senior Vice President & General Counsel
Karin Eastham
Independent Director
Arthur Blaine Bowman
Lead Independent Director
John Wendell Thompson
Independent Director
Philip W. Schiller
Independent Director
Caroline D. Dorsa
Independent Director
Robert S. Epstein
Independent Director
| Address |
5200 Illumina Way
San Diego California 92122
United States
|
|
Employees
|
- |
| Website |
http://www.illumina.com |
| Updated |
07/08/2019 |
| Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segment serve customers in the research, clinical and applied markets, and enable the adoption of a genomic solutions. |
